Combining MAP4K4 inhibition with immunotherapy to treat pancreatic cancer
Rational Combination of MAP4K4 Inhibition and Immunotherapy in Pancreatic Cancer
This study is exploring a new way to treat pancreatic cancer by using a combination of a special treatment that targets a protein involved in inflammation and immunotherapy, hoping to offer better options for patients facing this tough disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jesse Brown VA Medical Center NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10725148 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for pancreatic cancer by combining MAP4K4 inhibition with immunotherapy. The study focuses on understanding how the MAP4K4 protein, which is activated by inflammation, contributes to the aggressive nature of pancreatic cancer. By targeting this protein alongside immunotherapy, the researchers aim to improve treatment outcomes for patients who currently have limited options. The approach is based on the understanding that inflammation plays a significant role in the progression of pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with KRAS mutations.
Not a fit: Patients with other types of cancer or those without KRAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for pancreatic cancer patients, potentially improving survival rates.
How similar studies have performed: While targeting the KRAS pathway has been challenging, there is emerging evidence that similar combination therapies may improve outcomes in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
Chicago, United States
- Jesse Brown VA Medical Center — Chicago, United States (Active)
Researchers
- Principal investigator: Rana, Ajay Nmn — Jesse Brown VA Medical Center
- Study coordinator: Rana, Ajay Nmn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.